Outcomes in COVID-19 plitidepsin studies

0 0.5 1 1.5+ All studies -16% 2 163 Improvement, Studies, Patients Relative Risk Mortality -16% 2 163 RCTs -16% 2 163 RCT mortality -16% 2 163 Peer-reviewed 1% 1 135 Late -16% 2 163 Plitidepsin for COVID-19 c19early.org November 2025 Favorsplitidepsin Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ NEPTUNO Landete (RCT) 1% 0.99 [0.14-6.79] death 2/68 2/67 Improvement, RR [CI] Treatment Control NEREIDA PharmaMar (RCT) -36% 1.36 [0.19-9.57] death 5/22 1/6 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Late treatment -16% 1.16 [0.29-4.56] 7/90 3/73 16% higher risk All studies -16% 1.16 [0.29-4.56] 7/90 3/73 16% higher risk 2 plitidepsin COVID-19 studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Effect extraction pre-specified(most serious outcome) Favors plitidepsin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ NEPTUNO Landete (RCT) 1% 0.99 [0.14-6.79] 2/68 2/67 Improvement, RR [CI] Treatment Control NEREIDA PharmaMar (RCT) -36% 1.36 [0.19-9.57] 5/22 1/6 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Late treatment -16% 1.16 [0.29-4.56] 7/90 3/73 16% higher risk All studies -16% 1.16 [0.29-4.56] 7/90 3/73 16% higher risk 2 plitidepsin COVID-19 mortality results c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Favors plitidepsin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ NEPTUNO Landete (RCT) 1% 0.99 [0.14-6.79] death 2/68 2/67 Improvement, RR [CI] Treatment Control NEREIDA PharmaMar (RCT) -36% 1.36 [0.19-9.57] death 5/22 1/6 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Late treatment -16% 1.16 [0.29-4.56] 7/90 3/73 16% higher risk All studies -16% 1.16 [0.29-4.56] 7/90 3/73 16% higher risk 2 plitidepsin COVID-19 serious outcomes c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Effect extraction pre-specified(most serious outcome) Favors plitidepsin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ NEPTUNO Landete (RCT) 1% 0.99 [0.14-6.79] death 2/68 2/67 Improvement, RR [CI] Treatment Control NEREIDA PharmaMar (RCT) -36% 1.36 [0.19-9.57] death 5/22 1/6 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Late treatment -16% 1.16 [0.29-4.56] 7/90 3/73 16% higher risk All studies -16% 1.16 [0.29-4.56] 7/90 3/73 16% higher risk 2 plitidepsin COVID-19 Randomized Controlled Trials c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Effect extraction pre-specified(most serious outcome) Favors plitidepsin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ NEPTUNO Landete (RCT) 1% 0.99 [0.14-6.79] 2/68 2/67 Improvement, RR [CI] Treatment Control NEREIDA PharmaMar (RCT) -36% 1.36 [0.19-9.57] 5/22 1/6 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Late treatment -16% 1.16 [0.29-4.56] 7/90 3/73 16% higher risk All studies -16% 1.16 [0.29-4.56] 7/90 3/73 16% higher risk 2 plitidepsin COVID-19 RCT mortality results c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Favors plitidepsin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ NEPTUNO Landete (RCT) 1% 0.99 [0.14-6.79] death 2/68 2/67 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Late treatment 1% 0.99 [0.14-6.79] 2/68 2/67 1% lower risk All studies 1% 0.99 [0.14-6.79] 2/68 2/67 1% lower risk 1 plitidepsin COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.99 Effect extraction pre-specified(most serious outcome) Favors plitidepsin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ NEPTUNO Landete (RCT) 1% 0.99 [0.14-6.79] death 2/68 2/67 Improvement, RR [CI] Treatment Control NEPTUNO Landete (RCT) 52% 0.48 [0.04-5.16] death 1/70 2/67 NEREIDA PharmaMar (RCT) -36% 1.36 [0.19-9.57] death 5/22 1/6 NEREIDA PharmaMar (RCT) 25% 0.75 [0.10-5.77] death 3/20 1/5 Plitidepsin COVID-19 outcomes c19early.org November 2025 Favors plitidepsin Favors control